Literature DB >> 23099115

Are we discussing SUDEP?--A retrospective case note analysis.

B Waddell1, K McColl, C Turner, A Norman, A Coker, K White, R Roberts, C A Heath.   

Abstract

PURPOSE: Sudden unexplained death in epilepsy (SUDEP) is uncommon. Discussing the risk of SUDEP can be difficult, particularly in those where the risk is considered low, and previous studies have suggested that clinical practice varies widely. The Scottish Intercollegiate Guidelines Network (SIGN) suggest information on SUDEP is "essential" and National Institute of Clinical Excellence (NICE) recommend that "tailored information on the person's relative risk of SUDEP should be part of the counselling process…". The study aimed to evaluate if discussion of SUDEP risk is being documented in clinical records and to determine if there is an association between documented discussion and risk factors for SUDEP.
METHODS: A retrospective case note review was undertaken in those with an established diagnosis of epilepsy attending clinic between 1st January 2009 and 30th June 2009.
RESULTS: Overall, a documented SUDEP discussion was noted in 14/345 (4%) cases. Patients were statistically more likely to have a documented SUDEP discussion if they had ongoing generalised tonic-clonic seizures, with a trend also towards informing those non-compliant with medication.
CONCLUSION: Patients were more likely to be informed of SUDEP if they had potentially modifiable risk factors identified. There was, however, no documented evidence to suggest that SUDEP is being discussed in the majority of cases.
Copyright © 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23099115     DOI: 10.1016/j.seizure.2012.09.017

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  9 in total

1.  Can technology help reduce risk of harm in patients with epilepsy?

Authors:  Rohit Shankar; Craig Newman; Brendan McLean; Tamsyn Anderson; Jane Hanna Obe
Journal:  Br J Gen Pract       Date:  2015-09       Impact factor: 5.386

2.  Prevention of Sudden Death in Patients With Epilepsy.

Authors:  Murali K Kolikonda; Suneela Cherlopalle; Vivek C Shah; Steven Lippmann
Journal:  Prim Care Companion CNS Disord       Date:  2015-01-29

3.  Living With Epilepsy: It's Not Just a Matter of Quality.

Authors:  Chad Carlson
Journal:  Epilepsy Curr       Date:  2016 Nov-Dec       Impact factor: 7.500

4.  Steps to prevent SUDEP: the validity of risk factors in the SUDEP and seizure safety checklist: a case control study.

Authors:  Rohit Shankar; Matthew Walker; Brendan McLean; Richard Laugharne; Fucundo Ferrand; Jane Hanna; Craig Newman
Journal:  J Neurol       Date:  2016-06-22       Impact factor: 4.849

Review 5.  Sudden unexpected death in epilepsy.

Authors:  Shishir Nagesh Duble; Sanjeev V Thomas
Journal:  Indian J Med Res       Date:  2017-06       Impact factor: 2.375

6.  How the characteristics of pediatric neurologists in Latin America influence the communication of sudden unexpected death in epilepsy to patients and caregivers.

Authors:  Viviana Venegas; Carla Manterola; Jose De Pablo; Mariano Garcia; Sonia Ponce de León; Gabriel Cavada
Journal:  Epilepsia Open       Date:  2022-07-08

7.  Keeping patients with epilepsy safe: a surmountable challenge?

Authors:  Rohit Shankar; Craig Newman; Jane Hanna; Juliet Ashton; Caryn Jory; Brendan McLean; Tamsyn Anderson; Matthew Walker; David Cox; Liz Ewins
Journal:  BMJ Qual Improv Rep       Date:  2015-05-12

8.  Developing an Evidence-Based Epilepsy Risk Assessment eHealth Solution: From Concept to Market.

Authors:  Craig Newman; Rohit Shankar; Jane Hanna; Brendan McLean; Alex Osland; Cathryn Milligan; Abbie Ball; Caryn Jory; Matthew Walker
Journal:  JMIR Res Protoc       Date:  2016-06-07

9.  Has the Time Come to Stratify and Score SUDEP Risk to Inform People With Epilepsy of Their Changes in Safety?

Authors:  Rohit Shankar; Craig Newman; Alistair Gales; Brendan N McLean; Jane Hanna; Samantha Ashby; Matthew C Walker; Josemir W Sander
Journal:  Front Neurol       Date:  2018-04-27       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.